Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 3, 2009, Pages 319-327

  Westerlund, T ^a,b   Marklund, B ^b,c  

^a Apoteket AB   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c Halland County Council   (Sweden)

Author keywords

Assessment; Clinical outcomes; Drug related problems; Economic outcomes; Pharmaceutical care; Pharmacy interventions

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTITHYROID AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIURETIC AGENT; ESTROGEN; HYPNOTIC SEDATIVE AGENT; LAXATIVE; NARCOTIC ANALGESIC AGENT; PROGESTERONE; PROTON PUMP INHIBITOR; VASODILATOR AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ASSESSMENT; COST CONTROL; DRUG MISUSE; DRUG STORAGE; DRUG SURVEILLANCE PROGRAM; DRUG TREATMENT FAILURE; ECONOMIC EVALUATION; FEMALE; HOSPITALIZATION; HUMAN; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD REVIEW; PATIENT COUNSELING; PATIENT INFORMATION; PATIENT REFERRAL; PHARMACEUTICAL CARE; PHARMACIST; PHYSICIAN; PRIMARY MEDICAL CARE; SWEDEN;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMMUNITY PHARMACY SERVICES; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, THEORETICAL; PHARMACEUTICAL PREPARATIONS; PHARMACISTS; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; SWEDEN; YOUNG ADULT;

EID: 65549090590     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.01017.x     Document Type: Article

References (42)

1. van Mil F, ed. Proceedings of the International working conference on outcomes measurements in pharmaceutical care. Pharmaceutical Care Network Europe (PCNE) : Hillerød, Denmark, January 26-29, 1999 : 84.
2. MedicineNet.com http://www.medterms.com/script/main/art.asp?articlekey= 26227 (accessed 7 April 2008).
3. Johnson JA, Bootman JL 1995) Drug-related morbidity and mortality: a cost-of-illness model. Archives of Internal Medicine, 155, 1949 1956.
4. Ernst FR, Grizzle AJ 2001) Drug-related morbidity and mortality: updating the cost-of-illness model. Journal of the American Pharmaceutical Association, 41, 192 199.
5. Winterstein AG, Sauer BC, Hepler CD, Poole C 2002) Preventable drug-related hospital admissions. Annals of Pharmacotherapy, 36, 1238 1248. DOI. (Pubitemid 34755803)
6. Lazarou J, Pomeranz BH, Corey PN 1998) Incidence of adverse drug reactions in hospitalized patients: meta-analysis of prospective studies. Journal of the American Medical Association, 279, 1200 1205. (Pubitemid 28193431)
7. Pouyanne P, Haramburu F, Imbs JL, Bégaud B 2000) Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. British Medical Journal, 320, 1036. (Pubitemid 30198972)
8. Alonso HP, Otero Lopez MJ, Maderuelo Fernandez JA 2002) [Ingresos hospitalarios causados por medicamentos: Incidencia, características y coste]. Spanish Farm Hospital, 26, 77 89. (Pubitemid 34533210)
9. Beijer HJM, De Blaey CJ 2002) Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharmacy World and Science, 24, 46 54. (Pubitemid 34534816)
10. Mjörndal T, Danell Boman M, Hägg S et al. (2002) Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiology and Drug Safety, 11, 65 72. (Pubitemid 34269600)
11. von Euler M, Eliasson E, Ohlen G, Bergman U 2006) Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization. Pharmacoepidemiology and Drug Safety, 15, 178 184.
12. Fryckstedt J, Asker-Hagelberg C 2008 Läkemedelsrelaterade problem vanliga p medicinakuten Swedish Läkartidningen, 105, 894 898.
13. McDonnell PJ, Jacobs MR 2002) Hospital admissions resulting from preventable adverse drug reactions. Annals of Pharmacotherapy, 36, 1331 1336. DOI.
14. Gandhi TK, Weingart SN, Borus J et al. (2003) Adverse drug events in ambulatory care. The New England Journal of Medicine, 348, 1556 1564. (Pubitemid 36437933)
15. Gurwitz JH, Field TS, Harrold LR et al. (2003) Incidence and preventabilty of adverse drug events among older persons in the ambulatory setting. Journal of the American Medical Association, 289, 1107 1116. (Pubitemid 37430324)
16. Benrimoj SI, Langford JH, Berry G et al. (2000) Economic impact of increased clinical intervention rates in community pharmacy. A randomised trial of the effect of education and a professional allowance. Pharmacoeconomics, 18, 459 468.
17. Strand LM, Cipolle RJ, Morley PC, Frakes MJ 2004) The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty-five years of experience. Current Pharmaceutical Design, 10, 3987 4001. (Pubitemid 39591913)
18. Guerreiro MP, Cantrill JA, Pisco L, Martins AP 2005) Considerations on preventable drug-related morbidity in primary care. Part I - Impact of preventable drug-related morbidity. Revista Portuguesa de Clinica Geral, 21, 269 279.
19. Westerlund T, Almarsdóttir AB, Melander A 1999) Drug-related problems and pharmacy interventions in community practice. International Journal Pharmacy Practice, 7, 40 50. (Pubitemid 29219290)
20. Westerlund LOT, Marklund BRG, Handl WHA, Thunberg ME, Allebeck P 2001) Nonprescription drug-related problems and pharmacy interventions. Annals of Pharmacotherapy, 35, 1343 1349. DOI. (Pubitemid 33042064)
21. Andersson C, Brodin H, Nilsson JLG 2003) Pharmacist interventions in relation to patient drug-related problems. Journal of Social and Adminstrative Pharmacy, 20, 82 91. (Pubitemid 36807504)
22. Westerlund LOT, Björk HT 2006) Pharmaceutical care in community pharmacies: practice and research in Sweden. Annals of Pharmacotherapy, 40, 1162 1169. Epub 2006 May 30. DOI. (Pubitemid 43886976)
23. van Mil JWF, Westerlund LOT, Hersberger KE, Schaefer MA 2004) Drug-related problem classification systems. Annals of Pharmacotherapy, 38, 859 867. Epub 2004 Mar 30. DOI. (Pubitemid 38509068)
24. Ax F, Sollie M, Westerlund T 2007) Quality assurance of drug-related problem (DRP) documentation and patient follow-ups of interventions in Swedish community pharmacies (Poster presentation). The 67th International Congress of FIP : Beijing, September 5-6.
25. Ax F, Brnstad J-O, Gustafsson S, Nordqvist M, Westerlund T 2004) Development and application of counselling models to improve the detection of drug-related problems (DRPs) in Swedish community pharmacies (oral presentation). The 64th International Congress of FIP : New Orleans, September 9.
26. Westerlund T, Ax F, Brnstad J-O et al. (2005) Application of counselling models for the detection of drug-related problems (DRPs) and evaluation of resulting interventions in Swedish community pharmacies (poster presentation). The 65th International Congress of FIP : Cairo, September 7-8.
27. Buurma H, De Smet PAGM, Leufkens HGM, Egberts ACG 2004) Evaluation of the clinical value of pharmacists' modifications of prescription errors. British Journal of Clinical Pharmacology, 58, 503 511. (Pubitemid 39540454)
28. Sveriges Kommuner och Landsting (2007) Statistik om hälso-och sjukvrd samt regional utveckling 2006, p.23. Sveriges Kommuner och Landsting : Swedish. Stockholm.
29. Södra regionvrdsnämnden prislista (2008). Swedish. Lund.
30. Sveriges Kommuner och Landsting (2001) Patienter i sluten vrd r 2000. Sveriges Kommuner och Landsting : Swedish. Stockholm.
31. Guerreiro MP, Cantrill JA, Pisco L, Martins AP 2005) Considerations on preventable drug-related morbidity in primary care. Part II - Strategies to reduce the risk of preventable drug-related morbidity. Revista Portuguesa de Clinica Geral, 21, 447 459.
32. Viktil KK, Blix HS 2008) The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic and Clinical Pharmacology and Toxicology, 102, 275 280. Epub 2008 Jan 30. DOI.
33. Guignard AP, Couray-Targe S, Colin C, Chamba G 2003) Economic impact of pharmacists' interventions with nonsteroidal anti-inflammatory drugs. Annals of Pharmacotherapy, 37, 332 338. DOI. (Pubitemid 36249629)
34. Rodríguez-Monguió R, Otero MJ, Rovira J 2003) Assessing the economic impact of adverse drug effects. Pharmacoeconomics, 21, 623 650. (Pubitemid 36808215)
35. Scullin C, Scott MG, Hogg A, McElnay JC 2007) An innovative approach to integrated medicines management. Journal of Evaluation in Clinical Practice, 13, 781 788. (Pubitemid 47373606)
36. Blakey SA, Hixson-Wallace JA 2000) Clinical and economic effects of pharmacy services in geriatric ambulatory clinic. Pharmacotherapy, 20, 1198 1203.
37. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT 2008) Pharmacist care of patients with heart failure. A systematic review of randomized trials. Archives of Internal Medicine, 168, 687 694.
38. Howard RL, Avery AJ, Slavenburg S et al. (2007) Which drugs cause preventable admissions to hospital? A systematic review British Journal of Clinical Pharmacology, 63, 136 147. Epub 2006 Jun 26. DOI. (Pubitemid 46072098)
39. Odar-Cederlöf I, Oskarsson P, Öhlén G et al. (2008) Läkemedelsbiverkan som orsak till inläggning p sjukhus. Swedish Läkartidningen, 105, 890 893.
40. Koh Y, Kutty FB, Li SC 2005) Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender. Therapeutics and Clinical Risk Management, 1, 39 48.
41. Eckert-Lill C, Schmitz S, Schulz M (eds 2004). Die Hausapotheke. Konzepte erfolgreich umsetzen, p. 43 72. German. Govi Publ. Co.,: Eschborn. ISBN 3-7741-1018-2.
42. Blenkinsopp A, Celino G 2006) Long term conditions: integrating community pharmacy's contribution. Report 3. Royal Pharmaceutical Society of Great Britain and Webstar Health. http://www.rpsgb.org.uk/pdfs/ltcondintegcommphrept3. pdf (accessed 14 April 2008).